Abstract
Background: Programmed cell death 1 (PD-1) inhibitors have changed the landscape of management of advanced malignancies. However, they are often associated with cutaneous adverse effects that may prevent patients from completing treatment. Common adverse effects include morbilliform and psoriasiform rash, bullous pemphigoid-like eruptions, and dyspigmentation.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
